Lin Junyan has launched a new company that has achieved a valuation of approximately $2 billion. The company is focused on the emerging field of AI. Separately, Tonghe Pharmaceutical received FDA approval for its Kagliejing raw material, used to treat type 2 diabetes. Additionally, Qiangda Circuit is capable of producing PCB samples for 800G and 1.6T optical modules. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
IMPACT A new AI venture reaching a $2 billion valuation signals strong investor confidence and potential for future innovation in the AI sector.
RANK_REASON The cluster contains a significant funding event for a new AI company and a regulatory approval for a pharmaceutical product. [lever_c_demoted from significant: ic=1 ai=0.7]